Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy
In the prospective, open, observational study, we aim to evaluate whether circulating tumor DNA (ctDNA) can be the marker of the response to neoadjuvant therapy in stage I-III breast cancer.
Stage I-III Breast Cancer
Miller-Payne grading system, 3 years|Residual cancer burden (RCB), 3 years
In the prospective, open, observational study, we aim to evaluate whether circulating tumor DNA (ctDNA) can be the marker of the response to neoadjuvant therapy in stage I-III breast cancer.